W Cheng1, Z Zhang. 1. Obsterics and Gynecology Hospital, Shanghai Medical University.
Abstract
OBJECTIVE: To discuss the management of pituitary adenoma during gestation, labor and lactation. METHODS: This is a clinical retrospective analysis. 41 cases of pituitary adenoma in pregnancy and their treatment before conception and outcomes of pregnancy were analyzed. RESULTS: (1) The incidence of pituitary adenoma in pregnancy was 1.02%. (2) Women received bromocriptin only before pregnancy accounted for 85.77%. (3) Neurological symptoms occurred in 39.03% of the patients during gestation. (4) 30 patients (73.17%) kept on bromocriptin treatment during pregnancy, and no adverse effects on fetus were seen. (5) 75.00% of the patients were breastfeeding and no abnormal symptoms were shown. CONCLUSION: Bromocriptin treatment during pregnancy was safe and effective for women with pituitary adenoma, and breastfeeding was not contraindicated.
OBJECTIVE: To discuss the management of pituitary adenoma during gestation, labor and lactation. METHODS: This is a clinical retrospective analysis. 41 cases of pituitary adenoma in pregnancy and their treatment before conception and outcomes of pregnancy were analyzed. RESULTS: (1) The incidence of pituitary adenoma in pregnancy was 1.02%. (2) Women received bromocriptin only before pregnancy accounted for 85.77%. (3) Neurological symptoms occurred in 39.03% of the patients during gestation. (4) 30 patients (73.17%) kept on bromocriptin treatment during pregnancy, and no adverse effects on fetus were seen. (5) 75.00% of the patients were breastfeeding and no abnormal symptoms were shown. CONCLUSION:Bromocriptin treatment during pregnancy was safe and effective for women with pituitary adenoma, and breastfeeding was not contraindicated.